Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period

Journal of Paediatrics and Child Health

Volumn 48, Issue 11, 2012, Pages 1029-1032

  Shetty, Vinutha B ^a   Bower, Carol ^b,c   Jones, Timothy W ^a,c,d   Lewis, Barry D ^a   Davis, Elizabeth A ^a,c,d  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b KING EDWARD MEMORIAL HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

congenital adrenal hyperplasia; newborn screening; Western Australia

Indexed keywords

HYDROXYPROGESTERONE;

ABORIGINE; ADOLESCENT; ADRENAL CORTEX INSUFFICIENCY; ADULT; AMBIGUOUS GENITALIA; AUSTRALIA; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; DEHYDRATION; DELAYED DIAGNOSIS; ETHNIC DIFFERENCE; FAILURE TO THRIVE; FEEDING DISORDER; FEMALE; HUMAN; HYPERPIGMENTATION; INCIDENCE; INFANT; LIVE BIRTH; MALE; MORBIDITY; NEWBORN SCREENING; PHYSICAL EXAMINATION; PRENATAL DIAGNOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEX DIFFERENCE; SEX RATIO; STEROID 21 MONOOXYGENASE DEFICIENCY;

EID: 84868556072     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2012.02584.x     Document Type: Review

References (28)

1. Dittrich C, Sevelda P, Salzer H, et al,. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin. Eur. J. Cancer 2003; 39: 1129-40.
2. Pang SY, Wallace MA, Hofman L, et al,. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81: 866-74.
3. Balsamo A, Cacciari E, Piazzi S, et al,. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 1996; 98: 362-7.
4. Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, et al,. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101: 583-90.
5. Nimkarn S, Lin-Su K, Berglind N, Wilson RC, New MI,. Aldosterone-to-renin ratio as a marker for disease severity in 21-hydroxylase deficiency congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 2007; 92: 137-42.
6. Jeske YWA, McGown IN, Harris M, et al,. 21-hydroxylase genotyping in Australasian patients with congenital adrenal hyperplasia. J. Pediatr. Endocrinol. 2009; 22: 127-41.
7. Van der Kamp HJ, Noordam K, Elvers B, Van Baarle M, Otten BJ, Verkerk PH,. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics 2001; 108: 1320-4.
8. Strnadova KA, Votava F, Lebl J, et al,. Prevalence of congenital adrenal hyperplasia among sudden infant death in the Czech Republic and Austria. Eur. J. Pediatr. 2007; 166: 1-4.
9. Silveira EL, dos Santos EP, Bachega TAS, van der Linden Nader I, Gross JL, Elnecave RH,. The actual incidence of congenital adrenal hyperplasia in Brazil may not be as high as inferred-an estimate based on a public neonatal screening program in the state of Goias. J. Pediatr. Endocrinol. 2008; 21: 455-60.
10. Gleeson HK, Wiley V, Wilcken B, et al,. Two-year pilot study of newborn screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. J. Paediatr. Child Health 2008; 44: 554-9.
11. Prader A,. [Perfect male external genital development and salt-loss syndrome in girls with congenital adrenogenital syndrome.]. Helv. Paediatr. Acta 1958; 13: 5-14.
12. Nordenstrom A, Ahmed S, Jones J, et al,. Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm. Res. 2005; 63: 22-8.
13. Bhaskaran S, Nair V, Kumar H, Jayakumar RV,. Audit of care of patients with congenital adrenal hyperplasia due to 21-Hydroxylase deficiency in a referral hospital in South India. Indian Pediatr. 2006; 43: 419-23.
14. Torok D, Eckhardt G, Solyom J,. Twenty years experience in rapid identification of congenital adrenal hyperplasia in Hungary. Eur. J. Pediatr. 2003; 162: 844-9.
15. Peter S, McDigean G, Sandiford P, Smith T,. Congenital adrenal hyperplasia in the Bahamas due to 21-hydroxylase deficiency. West Indian Med. J. 2006; 55: 110-12.
16. Lee C-T, Tung Y-C, Hsiao P-H, Lee J-S, Tsai W-Y,. Clinical characteristics of Taiwanese children with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency in the pre-screening era. J. Formos. Med. Assoc. 2010; 109: 148-55.
17. Thil'en A, Nordenstrom A, Hagenfeldt L, von Dobeln U, Guthenberg C, Larsson A,. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics 1998; 101: E11.
18. Gozzi TG, Harris NP, McGown IN, et al,. Autopsy diagnosis of 21-hydroxylase deficiency CAH in a case of apparent SIDS. Pediatr. Dev. Pathol. 2005; 8: 397-401.
19. Grosse SD, Van Vliet G,. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia? Horm. Res. 2007; 67: 284-91.
20. Speiser PW,. Prenatal and neonatal diagnosis and treatment of congenital adrenal hyperplasia. Horm. Res. 2007; 68 (Suppl. 5): 90-2.
21. Cutfield WS, Webster D,. Newborn screening for congenital adrenal hyperplasia in New Zealand. J. Pediatr. 1995; 126: 118-21.
22. Liivak K, Tobi S, Schlecht H, Tillmann V,. Incidence of classical 21-hydroxylase deficiency and distribution of CYP21A2 mutations in Estonia. Horm. Res. 2008; 69: 227-32.
23. Brosnan PG, Brosnan CA, Kemp SF, et al,. Effect of newborn screening for congenital adrenal hyperplasia. Arch. Pediatr. Adolesc. Med. 1999; 153: 1272-8.
24. Kovacs J, Votava F, Heinze G, et al,. Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries. J. Clin. Endocrinol. Metab. 2001; 86: 2958-64.
25. Steigert M, Schoenle EJ, Biason-Lauber A, Torresani T,. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J. Clin. Endocrinol. Metab. 2002; 87: 4106-10.
26. Miller WL,. Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 1994; 78: 241-6.
27. Donaldson MD, Thomas PH, Love JG, Murray GD, McNinch AW, Savage DC,. Presentation, acute illness, and learning difficulties in salt wasting 21-hydroxylase deficiency. Arch. Dis. Child. 1994; 70: 214-18.
28. Nass R, Baker S,. Learning disabilities in children with congenital adrenal hyperplasia. J. Child Neurol. 1991; 6: 306-12.